{"commentary":{"count":33,"free_build_floor":8,"listing_floor":3,"by_channel":{"podcast":14,"youtube":13,"x_thread":6},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04697628\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"innovaTV 301","nct_id":"NCT04697628","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=innovatv-301-nct04697628. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources"},"registry":{"acronym":"innovaTV 301","arms":[{"description":"Tisotumab vedotin monotherapy","label":"Tisotumab vedotin","type":"EXPERIMENTAL"},{"description":"Investigator's choice of one chemotherapy treatment (topotecan, vinorelbine, gemcitabine, irinotecan, or pemetrexed)","label":"Chemotherapy","type":"ACTIVE_COMPARATOR"}],"collaborators":["Genmab"],"completion_date":{"date":"2026-01-15","type":"ACTUAL"},"conditions":["Cervical Cancer"],"enrollment":{"count":502,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"tisotumab vedotin","type":"DRUG"},{"name":"topotecan","type":"DRUG"},{"name":"vinorelbine","type":"DRUG"},{"name":"gemcitabine","type":"DRUG"},{"name":"irinotecan","type":"DRUG"},{"name":"pemetrexed","type":"DRUG"}],"last_update":"2026-02-24","lead_sponsor":"Seagen, a wholly owned subsidiary of Pfizer","official_title":"A Randomized, Open-Label, Phase 3 Trial of Tisotumab Vedotin vs Investigator's Choice Chemotherapy in Second- or Third-Line Recurrent or Metastatic Cervical Cancer","overall_status":"COMPLETED","phases":["PHASE3"],"primary_completion_date":{"date":"2023-07-24","type":"ACTUAL"},"primary_outcomes":[{"measure":"Overall Survival","timeFrame":"From randomization to date of death due to any cause or censoring date, whichever occurred first (maximum up to 25 months)"}],"references":[{"citation":"Jordan SE, Gonzalez-Martin A, Morlock R, Hubig L, Yonemori K, Eberst L, Zikan M, Kim HS, Banerjee S, Damian F, Salutari V, Henry S, Raimondo M, Kolinsky M, Woelber L, Tromp J, Hietanen S, Nishio S, Lee JY, Manso L, Cruz F, Barraclough L, Oaknin A, Van Nieuwenhuysen E, Randall L, Lo SH, Mutebi A, Abrahami D, Leary A, Vergote I. Patient-reported outcomes with tisotumab vedotin versus chemotherapy in patients with recurrent or metastatic cervical cancer: post hoc analyses from the open-label, randomized, phase 3 ENGOT-cx12/GOG-3057/innovaTV 301 trial. Int J Gynecol Cancer. 2026 Aug 11:104947. doi: 10.1016/j.ijgc.2026.104947. Online ahead of print.","pmid":"42680635","type":"DERIVED"},{"citation":"Yonemori K, Nishio S, Suzuki S, Hasegawa K, Yunokawa M, Yamaguchi S, Okamoto A, Nakamura K, Kamiura S, Fujiwara K, Katsumata N, Kobayashi H, Usami T, Mochizuki A, Takehara K, Whalley E, Noguchi H, Soumaoro I, Slomovitz B, Vergote I. Tisotumab vedotin in Japanese patients with recurrent or metastatic cervical cancer: results from the innovaTV 301/ENGOT-cx12/GOG-3057 trial. Int J Gynecol Cancer. 2026 Apr;36(4):104450. doi: 10.1016/j.ijgc.2025.104450. Epub 2025 Dec 31.","pmid":"41644383","type":"DERIVED"},{"citation":"Vergote I, Gonzalez-Martin A, Fujiwara K, Kalbacher E, Bagameri A, Ghamande S, Lee JY, Banerjee S, Maluf FC, Lorusso D, Yonemori K, Van Nieuwenhuysen E, Manso L, Woelber L, Westermann A, Covens A, Hasegawa K, Kim BG, Raimondo M, Bjurberg M, Cruz FM, Angelergues A, Cibula D, Barraclough L, Oaknin A, Gennigens C, Nicacio L, Teng MSL, Whalley E, Soumaoro I, Slomovitz BM; innovaTV 301/ENGOT-cx12/GOG-3057 Collaborators. Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer. N Engl J Med. 2024 Jul 4;391(1):44-55. doi: 10.1056/NEJMoa2313811.","pmid":"38959480","type":"DERIVED"}],"start_date":{"date":"2021-02-22","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer","url":"https://clinicaltrials.gov/study/NCT04697628"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/innovatv-301-nct04697628"}